enVVeno Medical Corp. (NASDAQ:NVNO) reported financial results for the second quarter of 2025, highlighting a net loss of $6.7 million, compared to a net loss of $5.0 million for the same period in 2024. This represents an increase in net loss by $1.7 million, or 35%. The company attributed the increase primarily to higher operating expenses, which rose by $1.6 million due to additional personnel costs, option grants, and non-recurring reserve and severance expenses. Additionally, there was a slight decrease in other income by $0.1 million. The company ended the quarter with $35.1 million in cash and investments, which is expected to fund operations through the third quarter of 2026, based on current expectations. The cash burn for the quarter was $3.8 million, aligning with the projected quarterly cash burn rate of approximately $4-5 million. enVVeno anticipates an increase in the cash burn rate upon the commercialization of the VenoValve. In terms of business updates, enVVeno Medical is preparing for a phased launch of its VenoValve, pending an FDA decision expected in the second half of 2025. The company also continues to progress with the IDE submission for enVVe, which is on track for the second half of 2025. The company has been actively addressing formal questions from the FDA regarding its VenoValve PMA application and has presented positive interim two-year data at the Society for Vascular Surgery 2025 Vascular Annual Meeting.